Research gaps in psoriasis: Opportunities for future studies - 18/12/13
Abstract |
Over the past 2 decades, considerable progress has been made to further elucidate the complex pathogenesis of psoriasis, facilitating the development of a new armamentarium of more effective, targeted therapies. Despite these important advances, substantial deficits remain in our understanding of psoriasis and its treatment, necessitating further research in many areas. In the sixth section of the American Academy of Dermatology Psoriasis Guidelines of Care, gaps in research and care were identified. We discuss the most important gaps in research that currently exist and make suggestions for studies that should be performed to address these deficits. These encompass both basic science and clinical research studies, including large, prospective epidemiologic studies to determine the true prevalence and natural history of psoriasis; further molecular studies in patients with psoriatic and psoriatic arthritis to understand the function of psoriasis susceptibility genes and to identify novel therapeutic targets; studies to examine the role of environmental factors in the development of psoriasis; further investigation of the relationship between psoriasis and cardiometabolic disease; studies that examine the role of adjunctive therapies such as psychological interventions in appropriate patient groups; and finally, studies to identify biomarkers of disease severity and treatment response to optimize patient therapy.
Le texte complet de cet article est disponible en PDF.Key words : adjunctive therapies, biologics, cardiovascular disease, comorbidities in psoriasis, comparative studies, disease severity, environmental factors in the development of psoriasis, future research studies, methotrexate, molecular studies in psoriatic and psoriatic arthritis, pathomechanisms and genetics of psoriasis, phototherapy, psoriasis, psoriasis guidelines, psoriasis treatment, psoriatic arthritis, psychological, research gaps, therapeutic targets, topical therapies
Abbreviations used : ACR, CRP, FDA, IFN, IL, MACE, MI, NB, NIH, PsA, RA, RCT, TNF, UV, VEGF
Plan
Funding sources: None. |
|
The authors' conflict of interest/disclosure statements appear at the end of the article. |
Vol 70 - N° 1
P. 146-167 - janvier 2014 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?